Ferring Pharmaceuticals study finds treat-to-target approach with faecal calprotectin monitoring improves outcomes in mild-to-moderate ulcerative colitis patients.

Ferring Pharmaceuticals announced findings from the OPTIMISE study, which assessed a treat-to-target (T2T) approach using faecal calprotectin (FC) monitoring for patients with mild-to-moderate ulcerative colitis (M2M UC). The study indicated that T2T significantly improved outcomes, with patients achieving 17-22% higher rates of clinical and endoscopic remission compared to traditional symptom-based methods. This research supports the T2T strategy for managing inflammatory bowel disease.

October 01, 2024
4 Articles